Abliva AB Revenue and Competitors

Lund,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Abliva AB's estimated annual revenue is currently $3.4M per year.(i)
  • Abliva AB's estimated revenue per employee is $201,000

Employee Data

  • Abliva AB has 17 Employees.(i)
  • Abliva AB grew their employee count by -6% last year.

Abliva AB's People

NameTitleEmail/Phone
1
Chief Medical OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Abliva AB?

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

keywords:N/A

N/A

Total Funding

17

Number of Employees

$3.4M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Abliva AB News

2022-04-17 - Isofol Medical : Full notice to attend the AGM 2022 (English)

The shareholders in Isofol Medical AB (publ), Reg. No. ... of Lidds AB and Glactone Pharma AB, a board member of Abliva AB and Innotext AB,...

2022-04-06 - Pusha T & Jay-Z Release New Pharrell-Produced Collab ‘Neck and Wrist’: Listen

... is six tracks with special appearances by Ab-Liva, Pharrell, Kash Doll and Clipse. Pusha T made another double EP release last month,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.3M17-6%N/A
#2
$1.4M170%N/A
#3
$1.4M17-23%N/A
#4
$1.7M19-5%N/A
#5
$3.1M2011%N/A